Chimerix Presents Preliminary Data on Brincidofovir in Liver Transplant Recipients With Adenovirus Infections at IDWeek in San Diego

By: via Benzinga
Chimerix, Inc. (NASDAQ: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.